Revolution Medicines annual depreciation and amortization
2018
2019
2020
2021
2022
2023
2024
2025
Revolution Medicines Depreciation & Amortization Growth & History (RVMD)
Revolution Medicines's depreciation and amortization was $7.8M for fiscal 2025.
View full Revolution Medicines company overviewRevolution Medicines annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $7.8M | $1.2M | +18.62% |
| 2024 | 2024-12-31 | $6.6M | $1.5M | +30.09% |
| 2023 | 2023-12-31 | $5.0M | $1.1M | +26.94% |
| 2022 | 2022-12-31 | $4.0M | $889,000 | +28.84% |
| 2021 | 2021-12-31 | $3.1M | $472,000 | +18.08% |
| 2020 | 2020-12-31 | $2.6M | $338,000 | +14.87% |
| 2019 | 2019-12-31 | $2.3M | $707,000 | +45.15% |
| 2018 | 2018-12-31 | $1.6M | — | — |
Revolution Medicines quarterly depreciation and amortization
Q1.19
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.4M | $157,000 | +6.85% |
| Q1 2026 | 2026-03-31 | $2.3M | $654,000 | +38.65% |
| Q4 2025 | 2025-12-31 | $4.7M | — | — |
| Q3 2025 | 2025-09-30 | $1.5M | −$113,000 | −6.88% |
| Q2 2025 | 2025-06-30 | $2.3M | $650,000 | +39.59% |
| Q1 2025 | 2025-03-31 | $1.7M | $152,000 | +9.87% |
| Q3 2024 | 2024-09-30 | $1.6M | $42,000 | +2.63% |
| Q2 2024 | 2024-06-30 | $1.6M | $419,000 | +34.26% |
| Q1 2024 | 2024-03-31 | $1.5M | $335,000 | +27.80% |
| Q3 2023 | 2023-09-30 | $1.6M | $600,000 | +60.00% |
| Q2 2023 | 2023-06-30 | $1.2M | $323,000 | +35.89% |
| Q1 2023 | 2023-03-31 | $1.2M | $304,000 | +33.74% |
| Q3 2022 | 2022-09-30 | $1.0M | $200,000 | +25.00% |
| Q2 2022 | 2022-06-30 | $900,000 | $100,000 | +12.50% |
| Q1 2022 | 2022-03-31 | $901,000 | $230,000 | +34.28% |
| Q3 2021 | 2021-09-30 | $800,000 | $100,000 | +14.29% |
| Q2 2021 | 2021-06-30 | $800,000 | $200,000 | +33.33% |
| Q1 2021 | 2021-03-31 | $671,000 | $39,000 | +6.17% |
| Q3 2020 | 2020-09-30 | $700,000 | $100,000 | +16.67% |
| Q2 2020 | 2020-06-30 | $600,000 | $100,000 | +20.00% |
| Q1 2020 | 2020-03-31 | $632,000 | $106,000 | +20.15% |
| Q3 2019 | 2019-09-30 | $600,000 | — | — |
| Q2 2019 | 2019-06-30 | $500,000 | — | — |
| Q1 2019 | 2019-03-31 | $526,000 | — | — |
Revolution Medicines depreciation and amortization trends
Over the last five fiscal years, Revolution Medicines's depreciation and amortization increased from $2.6M to $7.8M, a change of $5.2M. The latest reported quarter, Q2 2026, shows $2.4M.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Revolution Medicines source filings ↗